TransEnterix Lags Competitors in Key Financial Metrics

Got story updates? Submit your updates here. ›

A comparative analysis of TransEnterix and its competitors reveals that the medical device company lags behind its peers in key financial metrics such as net margins, return on equity, return on assets, revenue, and earnings per share. While TransEnterix's stock is trading at a lower price-to-earnings ratio, indicating it is more affordable, the company also has a higher beta, suggesting its share price is more volatile than the industry average.

Why it matters

As a publicly traded company, TransEnterix's financial performance and valuation are important factors for investors to consider. The analysis highlights areas where TransEnterix is underperforming relative to competitors, which could impact the company's long-term growth and shareholder returns.

The details

The data shows that TransEnterix has significantly lower net margins, return on equity, and return on assets compared to its peers. Additionally, TransEnterix's revenue and earnings per share trail its competitors. While TransEnterix's stock is trading at a lower price-to-earnings ratio, indicating it is more affordable, the company also has a higher beta of 2.56, suggesting its share price is 156% more volatile than the S&P 500 index. In contrast, TransEnterix's peers have an average beta of 1.76, meaning their share prices are 76% more volatile than the broader market.

• The financial data and analysis is current as of February 25, 2026.